



☐ Completed Enrollment

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

J2A-MC-GZGP - [ClinicalTrials.gov - NCT05869903](https://clinicaltrials.gov/ct2/show/study/NCT05869903)

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.

Trial Summary

Age Range	≥18 years
Conditions the trial is for	Obesity
What the trial is testing?	Orforglipron
Could I receive a Placebo?	Yes
Enrollment Goal	3127
Trial Dates	Jun 5, 2023 - Oct 2027
How long will I be in the trial?	Participants who have prediabetes, the study will last about 181 weeks and may include up to 39 visits.
Trial Phase	III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.



Participants Must:

- Have obesity or overweight
- If overweight, must also have one of the following: High blood pressure, high cholesterol, obstructive sleep apnea or heart disease
- Have at least 1 self-report of an unsuccessful at dietary effort to lose weight



Participants must not:

- Have Type 1 diabetes, Type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
- Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening
- Have family (first-degree relative) or personal history of MTC or MEN2 syndrome
- Have had a history of chronic or acute pancreatitis